Ge Yu-Xing, Xin Wen-Jun, Hu Neng-Wei, Zhang Tong, Xu Ji-Tian, Liu Xian-Guo
Pain Research Center, Department of Physiology, Zhongshan Medical School of Sun Yat-Sen University, Guangzhou, PR China.
Brain Res. 2006 Nov 6;1118(1):58-65. doi: 10.1016/j.brainres.2006.08.009. Epub 2006 Sep 1.
Clonidine, a specific alpha2-adrenergic receptor agonist, has been found to be effective for the treatment of neuropathic pain, the mechanism underlying the effect is, however, not well understood. Here, the effect of clonidine on long-term potentiation (LTP) of C-fiber evoked field potentials in spinal dorsal horn, which is a synaptic model of injury-induced hyperalgesia, was investigated. LTP of C-fiber evoked field potentials was recorded in the superficial layers of spinal dorsal horn in anesthetized adult Sprague-Dawley rats. Clonidine and other substances were applied locally at the recording spinal segments before or after LTP induction by tetanic stimulation. We found that (1) Clonidine completely blocked LTP induction, when applied 30 min before tetanic stimulation and depressed spinal LTP, when applied 30 min and 3 h after LTP induction. (2) The inhibitory effect of clonidine on spinal LTP had two phases: a fast phase lasting for about 3.5 h and a slow phase persisting for the rest time of experiments (up to 8 h after drug). (3) Spinal clonidine at low dose (10.7 micro g/100 micro l) depressed spinal LTP but not C-fiber baseline response and at higher dose (107 micro g/100 micro l) depressed both of them. (4) Pretreatment with alpha2-adrenergic receptor antagonist yohimbine completely blocked the inhibitory effect of clonidine. (5) Pretreatment with muscarinic receptor antagonist atropine, nitric oxide synthesis inhibitor l-NNA or cGMP inhibitor ODQ depressed the fast phase inhibition significantly and abolished the slow phase inhibition completely. These results suggest that clonidine may exert analgesic effect by depressing the synaptic plasticity in spinal dorsal horn, via activation of muscarinic receptor-NO-cGMP pathway.
可乐定是一种特异性α2 - 肾上腺素能受体激动剂,已被发现对治疗神经性疼痛有效,但其作用机制尚不清楚。在此,研究了可乐定对脊髓背角C纤维诱发场电位长时程增强(LTP)的影响,LTP是损伤诱导性痛觉过敏的突触模型。在麻醉的成年Sprague-Dawley大鼠的脊髓背角浅层记录C纤维诱发场电位的LTP。在强直刺激诱导LTP之前或之后,将可乐定和其他物质局部应用于记录脊髓节段。我们发现:(1)在强直刺激前30分钟应用可乐定可完全阻断LTP诱导,在LTP诱导后30分钟和3小时应用则可抑制脊髓LTP。(2)可乐定对脊髓LTP的抑制作用有两个阶段:快速阶段持续约3.5小时,缓慢阶段持续至实验剩余时间(药物应用后长达8小时)。(3)低剂量(10.7μg/100μl)的脊髓可乐定可抑制脊髓LTP,但不影响C纤维基线反应,高剂量(107μg/100μl)则两者均抑制。(4)用α2 - 肾上腺素能受体拮抗剂育亨宾预处理可完全阻断可乐定的抑制作用。(5)用毒蕈碱受体拮抗剂阿托品、一氧化氮合成抑制剂L - NNA或cGMP抑制剂ODQ预处理可显著抑制快速阶段的抑制作用,并完全消除缓慢阶段的抑制作用。这些结果表明,可乐定可能通过激活毒蕈碱受体 - NO - cGMP途径抑制脊髓背角的突触可塑性,从而发挥镇痛作用。